NCT03233776 2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2 Completed
Clinical Trials
9 trialsNCT04099901 2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2 Completed
NCT02589860 2022-01-10
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Indiana University
Withdrawn
NCT03704597 2018-10-15
Cryotherapy Against Oral Mucositis After High-dose Melphalan
Sahlgrenska University Hospital
Phase NA Unknown
NCT01653106 2017-06-27
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT00070616 2014-10-24
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support
Swedish Orphan Biovitrum
Phase 1 Completed
NCT00482846 2014-04-15
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT01402687 2013-07-16
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
Dana-Farber Cancer Institute
Completed
NCT00602147 2013-03-14
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
Vanderbilt-Ingram Cancer Center
Terminated